The present data would indicate that loss of GARP function would not be a valid strategy for PD therapeutics, but models in which gain of LRRK2 function is associated with cellular dysfunction support the concept that kinase inhibition might be therapeutically useful in PD patients (West, 2015). The gene discussed is LRRK2; the disease is Parkinson disease.